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Abstract The neural cell adhesion molecule L1 has
recently been shown to be expressed in pancreatic
adenocarcinoma (PDAC) cells. In this report, we demon-
strate that L1 is expressed by moderately- to poorly-
differentiated PDAC cells in situ, and that L1 expression
is a predictor of poor patient survival. In vitro, reduced
reactivity of an anti-L1 carboxy-terminus-specific antibody
was observed in the more poorly differentiated fast-growing
(FG) variant of the COLO357 population, versus its well-
differentiated slow-growing (SG) counterpart, even though
they express equivalent total L1. The carboxy-terminus of
L1 mediates binding to the MAP kinase-regulating protein
RanBPM and mutation of T1247/S1248 within this region
attenuates the expression of malignancy associated proteins
and L1-induced tumorigenicity in mice. Therefore, we
reasoned that the differential epitope exposure observed
might be indicative of modifications responsible for
regulating these events. However, epitope mapping dem-
onstrated that the major determinant of binding was
actually N1251; mutation of T1247 and S1248, alone or
together, had little effect on C20 binding. Moreover, cluster
assays using CD25 ectodomain/L1 cytoplasmic domain
chimeras demonstrated the N1251-dependent, RanBPM-
independent stimulation of erk phosphorylation in these
cells. Reactivity of this antibody also reflects the differen-
tial exposure of extracellular epitopes in these COLO357
sublines, consistent with the previous demonstration of L1
ectodomain conformation modulation by intracellular mod-
ifications. These data further support a central role for L1 in
PDAC, and define a specific role for carboxy-terminal
residues including N1251 in the regulation of L1 activity in
PDAC cells.
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Introduction
Pancreatic ductal adenocarcinoma (PDAC) has one of the
highest mortality rates of all cancers [1, 2]. Despite this, its
biology remains somewhat poorly understood. Studies have
identified key factors in PDAC etiology [3], which have
been incorporated into a timeline that has been in part
validated using transgenic mice [4, 5]. Although such a
timeline is significant in defining the onset of the disease, a
similar timeline has been difficult to establish for the
progression of the disease. Additionally, although almost all
patients present with late-stage disease due to a lack of
symptoms, several distinct presentations are observed with
regard to tumor growth and dissemination [1–3], suggesting
alternative mechanisms of progression and/or the presence
of tumor subtypes.
The neural cell adhesion molecule L1 (L1-CAM, CD171)
is a transmembrane protein of the immunoglobulin superfam-
ily (Fig. 3a) that regulates active neural processes [6]. L1
expression has also been described in non-neural tissues and
human tumor cells [7], where L1 correlates with poor
prognosis and advanced disease state in several tumor types
[8–10], and in serous neoplasms of the ovary L1 expression
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DOI 10.1007/s13277-010-0127-4increased with tumor grade and predicted poor response to
chemotherapy and shorter progression-free survival [10].
These data suggest a potential role for L1 in cancer
progression. Although a prior publication failed to detect
L1 in human PDAC samples [11], a subsequent report found
L1 expression in moderately- and poorly-differentiated
PDAC tumors, with the highest expression noted in the
most poorly differentiated cells [12], similar to our findings
with a larger dataset, which are reported herein.
L1’s role in regulating processes associated with inva-
sion make it well suited for use by an aggressive tumor.
Stable ectopic expression of L1 in fibroblastic and low-
metastatic melanoma cells drives constitutive MAP kinase
activation and induces the expression of invasion and
metastasis-associated genes, thereby promoting de novo
integrin utilization and concomitant enhanced migration
and invasion in vitro [13]. Moreover, L1 is fully trans-
forming and expressed at the invasive front of colon
cancers in situ [14], and ectopic expression of L1 in
endogenously L1-negative colon cancer cells bestows a
metastatic phenotype [15]. Importantly, the cytoplasmic
domain of L1 was required for this effect, although the
cytoplasmic domain alone was not sufficient to drive this
phenotype. A binding site for the MAP kinase activator
RanBPM was recently mapped to the carboxy-terminal 28
amino acids of L1 [16]. Mutation of both T1247 and S1248
within this region abrogated L1-induced erk-dependent
gene expression, cell migration, and tumor growth in
HEK293 cells and SKOV3ip ovarian carcinoma cells [17].
However, this dual mutation had no effect on RanBPM
binding to L1. It is not known if mutation of T1247 alone
would be sufficient, since S1248A alone had no effect in
this system, and the effect of T1247A alone was not tested.
Moreover, no evidence was provided for regulation of this
activity through post-translational modification (i.e., phos-
phorylation). This is important because erk2 can phosphor-
ylate S1248 in vitro [18]. Therefore, the relevance of this
double mutation to the regulation of L1 activity in cells or
tissues is not clear. We found that an antibody specific to
the L1 carboxy-terminus demonstrates differentiation-
dependent reactivity in the COLO357 cell system. To
investigate the mechanism responsible for this pattern, we
utilized recombinant proteins to define the epitope of this
antibody, and the corresponding regulation of erk activation
and L1 tail conformation by the identified residues.
Materials and methods
Cells
Panc1 cells were originally from ATCC. COLO357 cells
were from M. Korc (UCI, Irvine, CA, USA). The fast-
growing COLO357 subline, fast growing (FG), was from
R. Klemke (UCSD, San Diego, CA, USA). The slow-
growing COLO357 subline, slow growing (SG), was from
M. Vezeridis (Brown University, Providence, RI, USA).
M21 human melanoma cells were derived from the UCLA-
SO-M21 cell line, which was provided by Dr. DL Morton
(UCLA, Los Angeles, CA, USA). Panc1, COLO357, SG,
and FG cells were cultured in DMEM/10% fetal bovine
serum (FBS). M21 cells were grown in RPMI/10% FBS.
Panc1 cells were transfected with pCDNA3.1/Tac/L1
chimera constructs using Lipofectamine2000 (Invitrogen,
San Diego, CA, USA) and stable clones were derived by
zeocin resistance. Clones were assessed for Tac/L1 expres-
sion and positive clones pooled and maintained under
selection.
Antibodies
αL1 Carboxy-terminus (C20), αGST (110–218) and the
immunoblotting αCD25 (N19) polyclonal antibodies
(pAbs) were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). αCD25 monoclonal antibody (mAb)
(cl.22722) used for Flow cytometry (FACS) and cluster
assays was from R&D Systems (Minneapolis, MN,
USA). αRanBPM pAb was from Millipore (Bedford,
MA, USA). αL1 mAb 2C2 was from AbCam (Cam-
bridge, MA, USA) and has been described in detail
previously [19], αL1 mAb UJ127 was from Neomarkers/
LabVision (Fremont, CA, USA), αL1 mAb 5G3 was
generously provided by M. Just (eBioscience, San Diego,
CA, USA). αECD pAb was generated against purified L1
ectodomain and provided by W Stallcup (The Burnham
Institute, La Jolla, CA, USA). αFL pAb was generated
against L1 purified from human neuroblastoma cells using
a 5G3 immunoaffinity column. Both αECD and αFL have
been described previously [19].
Cluster assay
Stable CD25/L1 chimera-expressing Panc1 cells were
plated at 2.5×10
4/24-well and allowed to grow for 48 h
prior to serum starvation overnight. The plate was placed
on ice and the media replaced with ice-cold serum-free
media containing 10 μg/ml αCD25 mAb. Cells were
incubated 30 min on ice, washed, and fresh serum-free
media replenished. Cells were warmed to 37°C for 45 min
and lysates harvested and processed for immunoblotting.
Immunoprecipation
Cells were lysed in phosphate lysis buffer (PLB; 10 mM
NaPO4, 100 mM NaCl, 1% TX-100, 0.4% deoxycholate,
0.1% SDS, pH 7.5) containing Complete™ Protease
348 Tumor Biol. (2011) 32:347–357Inhibitor Cocktail (Roche Applied Science, Indianapolis,
IN, USA) supplemented with 10 mM PMSF, 1 mM NaF
and 10 mM Na3VO4, and incubated with the indicated
antibody (2 μg) overnight at 4°C. Antibodies were
precipitated with Protein-L sepharose4b beads (Pierce,
Rockford, IL, USA), recovered by centrifugation, washed,
and prepared for immunoblotting.
GST pull-down assay
GST-fusion proteins (1 μg) were incubated with the
indicated Panc1 lysates (250 μg) overnight at 4°C.
Glutathione-4b sepharose beads were added (10 μl) and
the samples incubated 2 h at 4°C before recovery of bead-
bound GST fusion proteins by centrifugation, washing and
preparation for immunoblotting.
Immunoblotting
Samples were separated by reducing sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE),
electroblotted to PVDF, sequentially incubated with
primary and horseradish peroxidase (HRP)-conjugated
secondary antibodies and visualized by ECL with PS-3
(Lumigen, Southfield, MI, USA). Gels were scanned on
an Epson 4490Photo Flatbed Scanner and band intensi-
ties were densitometrically analyzed using NIH Im-
age 1.61. Band intensities were normalized against the
appropriate loading control (i.e., erk2 or GST) and
compared to the indicated baseline comparison band,
w h i c hw a sd e f i n e da s1 . 0 .
Flow cytometry
FACS analysis and sorting was performed on a FACScali-
bur or FACSVantageSE, respectively (BD Biosciences,
Bedford, MA, USA), at the Moores UCSD Cancer Center
Flow Cytometry Shared Resource as described previously
[13, 19]. Gates were set with secondary antibody controls,
and propidium iodide was included to exclude dead and
dying cells.
Enzyme-linked immunosorbent assay
GST-proteins were immobilized on 96-well plates and
incubated with appropriate primary and HRP-conjugated
secondary antibodies and detected with TMB as described
previously [19]. Data was corrected for αGST signal as a
measure of fusion protein adsorption to the plate. In some
cases, data were confirmed using proteins captured on
glutathione-coated plates (Pierce/ThermoScientific, Rock-
ville, IL, USA) to prevent denaturing of the L1 fragments
during adsorption to plastic substratum.
L1 fusion proteins
(Prokaryotic) Unless otherwise indicated, pGEX GST-
fusion constructs were described previously [19], or
generated by site-directed mutagenesis using the appropri-
ate primers (Table 1) as described previously [19]. GST/
L1
1238–1257 and GST/L1
1249–1257 were created by ligation of
annealed and phosphorylated mini-exon primers into the
EcoRI site of pGEX/6P-1. All constructs were confirmed
by dideoxy sequencing at the Moores UCSD Cancer Center
DNA Sequencing Shared Resource. (Eukaryotic) Inserts
from the appropriate pGEX vectors were excised with
EcoRI and ligated into the EcoRI site of a pCDNA3.1 (zeo)
vector containing the ectodomain and transmembrane
sequences of the high-affinity IL2 receptor (CD25, Tac)
which had previously been inserted immediately upstream
between the NheI and HindIII sites of the vector.
Tissue samples and immunohistochemistry (IHC)
Samples were obtained under approved IRB protocol from
the UCSD Dept. of Pathology archives. Patient demograph-
ics and tissue characterization were published previously
[20]. Sections were deparaffinized, rehydrated, and rena-
tured before staining with UJ127 and development with
DAB chromagen as described previously [19].
Statistical analysis
Data shown is mean ± SD unless otherwise indicated.
Antibody binding differences were analyzed by two-tailed
Students t-Test. Survival was evaluated according to the
method of Kaplan-Meier using a univariate log-rank test.
Variables were coded as 1 for 100% L1-negative tumors
and 0 for those that demonstrated evidence of L1
expression in PDAC cells.
Results
L1 is expressed by moderately- to poorly-differentiated
PDAC cells in situ
We analyzed 92 human patient samples with the L1-
specific UJ127 mAb and found that L1 is not expressed
in normal ductal epithelium (Fig. 1a), nor well-
differentiated PDAC cells (Fig. 1b). L1 is however
detectable in poor- and undifferentiated/anaplastic/sarcoma-
toid PDAC cells (Fig. 1c), often at the tumor margin
(Fig. 1d), similar to what has been reported for colon cancer
[14]. Overall, our immunohistochemical analysis demon-
strated that 18/22 (82%) poorly-differentiated and 4/28
(14%) moderately-differentiated PDAC tumors were L1-
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well-differentiated PDAC samples (n=22). Importantly, L1
expression correlated with poor patient survival, with
median survival for L1-positive patients of 6 months with
a 5-year survival rate of 0%, versus median survival of L1-
negative patients of 21 months with a 5-year survival of
29%. Log-Rank P<0.001 (Fig. 1f).
Loss of C20 pAb binding correlates with malignancy/
differentiation in the COLO357 cell model
Sequential dissection of subcutaneous COLO357 PDAC
xenograft tumors and serial repassaging of fragments in
mice identified a fast-growing (FG), more malignant
variant, and a slow-growing (SG), less malignant variant
Primer type Primer sequence
Mutagenesis
−9 (1248 stop) F 5′-GGGGCCACTTCCTAAATCAACCCTGCCGTGG-3′
R5 ′-CCACGGCAGGGTTGATTTAGGAAGTGGCCCC-3′
−10 (1247 stop) F 5′-CAGGGGCCACTTAACCCATCAACCCTGCCG-3′
R5 ′-CGGCAGGGTTGATGGGTTAAGTGGCCCCTG-3′
−20 (1238 stop) F 5′-AAGAAGGAGAAGGAGGCGTGAGGGGGCAATGA-3′
R5 ′-TCATTGCCCCCTCACGCCTCCTTCTCCTTCTT-3′
−28 (1229 stop) F 5′-TTGGCCAGTACTAAGGCAAGAAGGAGAAGGA-3′
R5 ′-TCCTTCTCCTTCTTGCCTTAGTACTGGCCAA-3′
P1249A F 5′-CAGGGGCCACTTCCGCCATCAACCCTGCCG-3′
R5 ′-CGGCAGGGTTGATGGCGGAAGTGGCCCCTG-3′
N1251A F 5′-GCCACTTCCCCCATCGCCCCTGCCGTGGCCC-3′
R5 ′-GGGCCACGGCAGGGGCGATGGGGGAAGTGGC-3′
N1251D F 5′-ACTTCCCCCATCGACCCTGCCGTGGCCC-3′
R5 ′-GGGCCACGGCAGGGTCGATGGGGGAAGT-3′
P1252A F 5′-GCCACTTCCCCCATCAACGCTGCCGTGGCCCTA-3′
R5 ′-TAGGGCCACGGCAGCGTTGATGGGGGAAGTGGC-3′
E1257A F 5′-GCCGTGGCCCTAGCATAGGAATTCCCG-3′
R5 ′-CGGGAATTCCTATGCTAGGGCCACGGC-3′
Mini-Exon
1238–1257 F 5′-AATTCGCAGGGGGCAATGACAGCTCAGGGGCC
ACTTCCCCCATCAACCCTGCCGTGGCCCTAGAAG-3′
R5 ′-AATTCTTCTAGGGCCACGGCAGGGTTGATGGGG
GAAGTGGCCCCTGAGCTGTCATTGCCCCCTGCG-3′
1249–1257 F 5′-AATTCCCCATCAACCCTGCCGTGGCCCTAGAAG-3′
R5 ′-AATTCTTCTAGGGCCACGGCAGGGTTGATGGGG-3′
1238–1257 T1247A F 5′-AATTCGCAGGGGGCAATGACAGCTCAGGGGCCG
CTTCCCCCATCAACCCTGCCGTGGCCCTAGAAG-3′
R5 ′-AATTCTTCTAGGGCCACGGCAGGGTTGATGGGG
GAAGCGGCCCCTGAGCTGTCATTGCCCCCTGCG-3′
1238–1257 S1248A F 5′-AATTCGCAGGGGGCAATGACAGCTCAGGGGCCA
CTGCCCCCATCAACCCTGCCGTGGCCCTAGAAG-3′
R5 ′-AATTCTTCTAGGGCCACGGCAGGGTTGATGGGG
GCAGTGGCCCCTGAGCTGTCATTGCCCCCTGCG-3′
1238–1257 TS1247/48AA F 5′-AATTCGGCAATGACAGCTCAGGGGCCGCTGCCC
CCATCAACCCTGCCGTGGCCCTAGAAG-3′
R5 ′-AATTCTTCTAGGGCCACGGCAGGGTTGATGGGG
GCAGCGGCCCCTGAGCTGTCATTGCCG-3′
1238–1257 TS1247/48EE F 5′-AATTCGGCAATGACAGCTCAGGGGCCGAAGAAC
CCATCAACCCTGCCGTGGCCCTAGAAG-3′
R5 ′-AATTCTTCTAGGGCCACGGCAGGGTTGATGGG
TTCTTCGGCCCCTGAGCTGTCATTGCCG-3′
Table 1 Primers used to con-
struct recombinant proteins
350 Tumor Biol. (2011) 32:347–357[21]. While the SG subline exhibits a highly differentiated
epithelial phenotype in culture, including strict monolayer
growth and contact inhibition, FG cells exhibit a moderate- to
poorly-differentiated phenotype, including three-dimensional
growth and lack of contact inhibition. When mixed in equal
ratios, this population did not drift, and displayed phenotypic
characteristics of the parental COLO357 cells [21]. Thus,
these lines represent a unique cell system to study PDAC
progression. Somewhat unexpectedly, the parental
COLO357 population (Fig. 2) and both sublines (Fig. 3b)
express L1 in vitro, and L1 appears to function in the growth
or survival of these cells since we were unable to flow-sort
stable high- and low-L1-expressing subpopulations of the
COLO357, SG and FG populations. Figure 2 shows a
representative experiment whereby high- and low-L1
expressing COLO357 subpopulations were flow-sorted
(Fig. 2a) and 10 days later each population was resorted
such that the lowest expressers were recovered from the
1Xlow-sorted population and the highest expressers from the
1Xhigh-sorted population. Two weeks later, the highest
expression in the “low” population was identical to that in
the “high” population (Fig. 2c), in stark contrast to their
expression levels after the first sort (Fig. 2b).
Importantly, while the ectodomain-reactive UJ127 mAb
demonstrates equivalent quantities of L1 protein in SG and
FG cells, the C20 pAb directed to the L1 carboxy-terminus
barely detects FG cell L1 under the denaturing conditions
Fig. 1 L1 is expressed by poorly differentiated PDAC cells in situ.
UJ127 mAb visualized with DAB chromogen (brown). a Normal
pancreas. b A well-differentiated tumor duct invading perineurally.
Nerve bundle, brown. c Poorly-differentiated PDAC tumor cells at the
margin. d High power image of c. e Immunohistochemical summary. f
Kaplan–Meier analysis of patient survival
Fig. 2 Sorted low L1-expressing Panc1 cells quickly revert to their
original expression levels. a UJ127 FACS-sort profile of parental cells
and derived L1-high- and L1-low-expressing subpopulations at the
time of sorting. b Overlay of sorted populations onto the parental
population (solid) immediately after the first sort. c FACS profiles of
L1-high- and L1-low-expressing subpopulations 2 weeks after second
sort. Controls are overlapped (solid)
Tumor Biol. (2011) 32:347–357 351of immunoblotting (Fig. 3b). L1 is a known proteolytic
target of both ADAMs and serine proteases [22, 23]
(Fig. 3a). Therefore, the possibility existed that the lack of
C20 reactivity in the high molecular weight protein could
represent ADAMs-mediated proteolysis of cell surface L1,
yielding a C20-reactive 30KDa product and a C20-
unreactive cell-associated 195KDa product lacking the
cytoplasmic domain. Indeed, immunoblotting demonstrates
fragments consistent with ADAMs proteolysis in FG cells,
while SG cells display fragments consistent with serine
proteolysis (Fig. 3c). Further corroborating these data is the
fact that the 195KDa ectodomain fragment could be
detected in media conditioned by FG, but not SG cells
(Fig. 3d). However, immunoblotting further verifies the
lack of C20 reactivity in the 30KDa fragment comprising
the transmembrane and cytoplasmic sequences in FG cells
specifically; M21 human melanoma cells demonstrate
substantial C20 signal in the 30-KDa fragment (Fig. 3c),
suggesting that obscuring of critical residues is responsible
for loss of C20 reactivity in FG cells. That the cytoplasmic
tail is not being further proteolyzed is demonstrated by
reprobing with the αFL pAb, which was generated against
the full-length protein and demonstrates equivalent amounts
of identically migrating protein in both lines (Fig. 3e).
Mapping the epitope requirements of the C20 pAb
L1 contains two alternatively spliced small exons, one
amino-terminal (exon2) and one in the cytoplasmic domain
(exon27). Both exons are present in the neuronal isoform,
and absent from the nonneuronal isoform [24]. Therefore,
the possibility existed that the differential C20 binding
observed in FG and SG cells might reflect differential
isoform expression. Using recombinant proteins, we found
that C20 detects both isoforms equivalently (Fig. 4a),
demonstrating that the alternatively-spliced exon27 is not
responsible for differential C20 reactivity.
The manufacturer (Santa Cruz Biotechnology) described
the C20 immunogen as being very near the carboxy-
terminus of L1. Therefore, we assessed the ability of C20 to
recognize sequential truncations of the GST/L1 cytoplasmic
domain
1144–1257 protein. We engineered −9( L 1
1144–1248),
−10 (L1
1144–1247), −20 (L1
1144–1238), and a −28 (L1
1144–
1229) mutant that removes the entire L1 sequence carboxy-
terminal to the ankyrin-binding site [25]—this region
encompasses the RanBPM binding site [16]. By enzyme-
linked immunosorbent assay (ELISA), C20 binding was
completely lost with the first deletion (Fig. 4b, left panel),
indicating that a primary epitope requirement exists within
the last nine amino acids of L1,
1249PINPAVALE
1257.
Presuming that the antibody might have been generated
against a 20-mer encoding the absolute carboxy-terminal
amino acids of L1 (hence, the name “C20”), we synthesized
a protein encoding this sequence (L1
1238–1257), as well one
encoding the last nine amino acids (L1
1249–1257), deletion of
which completely abrogated C20 binding to the GST/L1
cytoplasmic domain protein. In contrast to the effect of
deleting the
1249PINPAVALE sequence, this sequence alone
only recapitulated 22% of the binding observed with
L1
1238–1257 (Fig. 4b, right panel). This demonstrates that
although residues within the nine carboxy-terminal residues
are required for C20 binding, they alone are not sufficient
for full binding, further suggesting the presence of
additional critical residues in the previous 11 amino acid
stretch (
1238AGGNDSSGATS
1248).
Within this sequence, T1247 and S1248 have been
reported to be phosphorylated [18, 26]. Additionally, dual
alanine substitution of T1247 and S1248 has been shown to
Fig. 3 C20 reactivity correlates with differentiation/malignancy in the
COLO357 system. a Schematic of the L1 domain structure and
processing by proteases. Ig immunoglobulin, FN fibronectin. b
Immunoblotting demonstrates that the C20 epitope is masked in the
less-differentiated FG variant of COLO357, in contrast to the more-
differentiated SG variant. Erk2, loading control. c Immunoblotting of
whole cell lysates demonstrates that FG cells predominantly utilize
ADAMs proteases to cleave L1, while SG cells predominently utilize
serine proteases to cleave L1. M21, melanoma control. Relative
migration shown on left in KDa. d Immunoblotting of conditioned
media corroborates the data in c. Erk2, loading control. e Immuno-
blotting demonstrates that proteolysis does not account for loss of C20
reactivity, since the 30-KDa ADAMs fragment resolves as the same
molecular weight in FG and M21 lysates, but is undetectable by C20
in the FG lysate specifically
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tion and enhanced tumorigenicity in ovarian cancer cells
[17]. To test the potential involvement of these residues in
affecting C20 binding, we individually substituted these
residues with alanine in the GST/L1
1238–1257 protein. These
mutations caused less than 25% reduction of C20 binding
versus the wild-type protein (Fig. 4c). Moreover, alanine
substitution of both residues at once did not appreciably
increase the effect on C20 binding, nor did mutation of both
residues to glutamic acid, whose negative charge mimics
that of phosphate modification. In contrast, alanine substi-
tution of appropriate residues in the last nine amino acids
(
1249PINPAVALE) of the GST/L1
1144–1257 protein demon-
strated that N1251 is critical for C20 binding (Fig. 4d);
surprisingly, no effect was observed with substitution of
either surrounding proline (P1249 or P1252) or the
carboxy-terminal glutamic acid (E1257). The other residues
of this region constitute small, aliphatic amino acids (I1250,
V1254, L1256), or alanine itself (A1253, A1255); hence,
alanine substitution was not performed. It should be noted
that we examined four distinct lots of C20, produced over
the past 5 years, and found these epitope requirements to be
maintained.
Since the N1251A mutation demonstrated such a
pronounced effect on C20 binding in our recombinant
proteins, we reasoned that modification of this residue
might be responsible for the loss of signal noted in the FG
cells. Asparagine is not subject to phosphorylation; how-
ever, asparagine deamidation has been demonstrated in
various systems [for review, see 27]. Asparagine deamida-
tion results in the production of aspartate and iso-aspartate
endproducts, and iso-aspartate can be converted to aspartate
by a “repair” mechanism involving protein-L-isoAsp-O-
methyltransferase. However, both alanine and aspartic acid
mutations of N1251 were equally effective in blocking C20
binding by ELISA (Fig. 4e) and immunoblot (Fig. 4f),
suggesting that the disparate C20 reactivity with SG and
FG cells are not due to different levels or activities of this
enzyme and thus correspondingly differential rates of iso-
aspartate to aspartate “repair”.
C20 reactivity in the L1 cytoplasmic domain reflects UJ127
reactivity in the L1 ectodomain
Previously, we found that the conformation of the L1
ectodomain is regulated by, or reflected in, the serine/
threonine phosphorylation state of the L1 cytoplasmic
domain in general, and the phosphorylation state of T1172
in particular [19]. To determine if the differential C20
reactivity exhibited by the SG and FG subpopulations is
associated with distinct conformational states of L1 on the
cell surface, we performed FACS analysis with the
conformationally sensitive 5G3 mAb, which recognizes a
disulfide-stabilized epitope within amino acids 57–175
spanning the end of the Ig1 and beginning of Ig2 domains
at the membrane-distal amino-terminal end of L1 [19, 28].
As a reference, we used the UJ127 mAb, which recognizes
a linear epitope in the membrane-proximal FN4 domain
[19]. Binding of these antibodies reflects the conformation
of the L1 ectodomain [19]. SG cells demonstrate identical
5G3 and UJ127 signal (Fig. 5a). In contrast, FG 5G3
reactivity is more than double UJ127 (mean fluorescence
intensity 104.7 vs. 45.9). However, since 5G3 signal is
identical in SG and FG cells, the actual difference is a
reduction of FG UJ127 signal. This differential UJ127
epitope exposure was not limited to the live cell conditions
of FACS, as both 5G3 and UJ127 immunoprecipitated
similar amounts of L1 from SG cells, but UJ127 immuno-
precipitated significantly less L1 than 5G3 from FG
detergent lysates (Fig. 5b). Differential reactivity such as
this has been linked previously to T1172 phosphorylation at
Fig. 4 N1251 is a critical determinant of C20 binding. a ELISA of
GST fusion proteins demonstrates that C20 recognizes both isoforms
of L1. NN nonneuronal. b–d Truncation (b) and substitution (c,d)
analysis demonstrates the requirement for the carboxy-terminal 9
amino acids, and the critical importance of N1251 for C20 binding by
ELISA. e,f ELISA titration analysis (e) and immunoblotting (f) verify
the data in d, extend it to N1251D, and confirm that the C20 epitope
requirements are maintained under denaturing conditions
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[19]. Consistent with more T1172-unphosphorylated L1 in
the SG cells, the T1172-phosphorylation sensitive 2C2
mAb [19, 29] is much more reactive with L1 from SG cells
(Fig. 5c). It should be noted that the immunoprecipitated
products shown in Fig. 5b and c represent the full-length L1
species: since 2C2 recognizes the cytoplasmic domain, it is
not capable of immunoprecipating the 195 kDa species, but
still demonstrates the presence of a doublet that is
consistent with the data shown in Fig. 5b using
ectodomain-specific antibodies. Moreover, since the cells
appear to shed the 195 KDa into their culture media, it is
unlikely that there would be 195-KDa species that remains
cell associated and therefore in the cell lysates used for
immunoprecipation.
The significance of these data is highlighted by the fact
that the membrane–distal end of the L1 cytoplasmic domain
has been shown to loop back onto the membrane–proximal
end in a manner dependent on the integrity of membrane-
proximal (KRSK
1147) and membrane–distal (KKEK
1235)
dibasic motifs [29]. Thus, N1251 modification may impact
aspects of L1 biology through structural modification and/
or destabilization of this region, and concomitant regulation
of cytoplasmic domain folding. This is potentially impor-
tant because the conformation of the L1 cytoplasmic
domain regulates the availability of tyrosine and threonine
residues to kinases [29]. To examine the role of N1251 in
regulating L1 cytoplamic domain function, we engineered
chimeras encoding the ectodomain and transmembrane
domain of the high-affinity IL2 receptor (IL2Rα, CD25,
Tac), linked to the L1 cytoplasmic domain (Tac/L1
1144–
1257). In isolation, Tac is a monomeric protein that lacks the
ability to signal in the absence of the other heterodimer
IL2R partners (i.e., IL2Rβ and IL2Rγ)[ 30], which are not
expressed by pancreatic epithelial cells. We found that Tac/
L1
1144–1257 multimerizes, a process that is stable enough to
withstand the rigors of reducing SDS-PAGE (Fig. 5d).
Importantly, whereas 2C2 recognizes these aggregates as
well as the monomeric species, C20 fails to recognize the
aggregate forms (Fig. 5d), demonstrating that critical
determinants of C20 binding are functionally involved in
mediating this multimerization process, and are thereby
obscured in so doing.
As noted above, in the absence of IL2R heterodimer
partners (i.e., IL2Rβ and IL2Rγ), Tac lacks the ability to
signal. In response to clustering, however, chimeras such as
these have been shown to signal through the intracellular
fusion sequences [31]. We found that clustering of Tac/L1
cytoplasmic domain chimeras induced erk phosphorylation
in a manner attenuated by mutation of N1251 to either
alanine or aspartic acid (Fig. 5e). N1251 does not appear to
be a mediator of RanBPM-L1 interactions, however, as
mutation of N1251 did not negatively affect the binding of
L1 constructs to RanBPM (Fig. 5f).
Discussion
Using a panel of 92 patient samples including normal
pancreas and all grades of PDAC, we show that the neural
cell adhesion molecule is expressed by moderately- and
poorly-differentiated PDAC cells in situ. These data may be
an underestimate, since margin tissue was not available for
all samples analyzed, and we found that L1 expression was
often more prominent at the tumor margin. More impor-
tantly, L1 expression correlates with poor survival in our set
of PDAC patients, similar to what has been reported in
colon cancer [14]. We additionally found that L1 expression
Fig. 5 C20 reactivity correlates with the availability of the UJ127
epitope in the L1 ectodomain. a FACS analysis of cell surface L1
demonstrates reduced UJ127 reactivity in FG cells versus SG cells. b
Immunoprecipitation analysis demonstrates that UJ127 immunopreci-
pitates less L1 than 5G3 from FG cells. c Immunoblot of the lysates
from b with the 2C2 mAb, whose binding is blocked by T1172
phosphorylation. Erk2, loading control. d Reducing immunoblot of
Tac-L1 constructs expressed in Panc1 cells with 2C2 or C20. *Shorter
2C2 exposure verifies that upper species are detectable at an exposure
equivalent to that shown for C20 (i.e., monomer band intensities are
equal). Relative migration of protein standards indicated on the left in
KDa. UJ127, loading control and verification of lack of C20 reactivity
with endogenous L1 in these cells. e Clustering of Tac-L1 cytoplasmic
chimeras induces erk phosphorylation in an N1251-dependent manner.
Erk2, loading control. f GST-pulldown analysis demonstrates that
N1251 is not required for RanBPM interaction with L1. GST, loading
control
354 Tumor Biol. (2011) 32:347–357is tightly controlled in PDAC cells, and FACS-sorted low-
expressing subpopulations were unstable, and quickly
reverted to parental levels. These data are consistent with
L1 imparting a selective advantage in vitro. This proposi-
tion is actually predicted by a prior work in which L1 was
identified from a library of genetic suppressor elements as
required for the growth of breast cancer cells [32]. This
report showed that suppression of L1, either functionally or
at the level of expression, repressed growth and caused
mitotic catastrophe in L1-positive breast, colon, and
cervical carcinoma cells, without effect on normal breast
epithelial cells or fibroblasts, indicating that L1 is required
once it is expressed.
Mechanistically, our data demonstrate a loss of reactivity
with the carboxy-terminus-specific antibody C20 in less
differentiated FG cells, to the exclusion of their well-
differentiated and less malignant counterpart SG cells.
Importantly, we have found that poorly differentiated
PDAC lesions demonstrate reduced C20 reactivity in situ,
while C20 strongly detects nerves in the same sections (not
shown). However, the polyclonal nature of C20 and the
presence of parts of the C20 epitope sequence in other, non-
L1-related proteins promotes some detection of L1-negative
cells and structures, hampering its utility in IHC. It is
important to note, however, that the lack of C20 signal in
known-L1-positive PDAC cells in situ cannot be explained
by this “cross-reactivity”. As such, our in situ data
corraborate our in vitro data.
Since the L1 cytoplasmic domain does not contain
consensus motifs for intracellular proteases (e.g., calpain),
and since we accordingly do not detect proteolytic cleavage
of the L1 cytoplasmic domain in a manner suggesting
removal of this epitope, we propose that post-translational
modification is responsible for the observed loss of
reactivity. Although T1247 and S1248 near the L1
carboxy-terminus have been implicated in regulating
MAP-kinase activation and gene expression associated with
the L1-induced phenotype of ovarian cancer cells [17],
epitope mapping instead demonstrates that modification of
N1251 in the carboxy-terminal nine amino acids attenuates
the binding of C20. As such, mutation of N1251 to either
alanine, or one product of asparagine deamidation, aspartic
acid, almost completely abrogated antibody binding. This is
highly significant since glutamine–glutamate modification
Fig. 6 Model of L1 conforma-
tional regulation by cytoplasmic
modifications. L1 has been
shown to exist in distinct
conformations on the cell
surface [19]. These conforma-
tions have been shown to
involve T1172 phosphorylation
[19], and T1172 phosphoryla-
tion has been shown to be
regulated by the conformation of
the L1 cytoplasmic tail [29]. We
propose a model whereby T1172
availability is regulated at least
in part by unfolding of the L1
cytoplasmic domain that is
triggered by deamidation of
N1251. The ramifications of this
event (e.g., proteolysis and sig-
naling) are shown. Y tyrosine,
N asparagine, D aspartate,
isoD iso-aspartate
Tumor Biol. (2011) 32:347–357 355has been shown to regulate receptor multimerization,
putatively by reducing electrostatic repulsion between
helices [33], and similar mechanisms have been proposed
for asparagine–aspartate conversion including the regula-
tion of peptide hormone dimerization [34] and activation of
extracellular matrix molecules [35]. Moreover, the deami-
dation of specific asparagines to the exclusion of neighbor-
ing asparagines has been shown to regulate protein
structure and function [36]. Therefore, the relative abun-
dance of deamidated N1251 in malignant PDAC cells
might provide a regulatory mechanism for controlling L1
activity.
While it is possible that N1251 modification directly
regulates erk activation, its role could also be indirect. The
Neural Network Prediction program (http://npsa-pbil.ibcp.
fr/) predicted that the region at the end of the L1
cytoplasmic domain forms a random coil; however, the
region around N1251 contains two prolines separated by a
dipeptide linker with a small aliphatic residue immediately
after both prolines. Though much less constrained overall,
this sequence is similar to the glycine/proline tripeptide
repeat sequence of collagen molecules that provides the
primary impetus for their coiled coil structure [37].
Therefore, N1251 modification might indirectly promote
unfolding of the L1 cytoplasmic domain as described
previously [29]. Such a mechanism may also be responsible
for the dramatic phenotype observed in T1247A/S1248A
mutants described previously [17]. Moreover, the regulation
of specific patterns of extracellular proteolysis by these
events could also indirectly lead to differential signaling
through erk and other pathways as has been demonstrated
previously [7, 19, 22, 23]. A model illustrating the
conformational regulation of L1 activity by these events is
shown in Fig. 6.
In summary, we propose a model in which modification
of N1251 of L1 represents a means of regulating erk
activation by the carboxy-terminal region of L1. This
region has been shown previously to regulate erk activation
via both RanBPM-dependent and RanBPM-independent
mechanisms [16, 17]. N1251 does not appear to be
involved in RanBPM binding to L1; therefore, the N1251
mechanism may be indirect, by promoting conformational
alterations to the L1 cytoplasmic domain. Indeed, in this
report, we show that C20 reactivity reflects the presence of
a distinct conformation of the L1 ectodomain, consistent
with prior reports of L1 ectodomain conformation regula-
tion by cytoplasmic domain modification [19]. While we
recognize the limitations of our studies utilizing recombi-
nant proteins, these data are consistent with our previous
observations on the flexibility of the L1 ectodomain and
cytoplasmic domain, and the inter-regulated nature of each
[19, 29]. We further relate our recombinant in vitro data to
studies of endogenous L1 and L1 chimeras expressed in
PDAC cells. Findings such as these continue to advance
our understanding of L1 biology and the role of specific
sequences, especially within the cytoplasmic domain,
which is relatively understudied.
Acknowledgements We thank Dr. C Behling for tissue sample
procurement and analysis. S Silletti is an American Cancer Society
Research Scholar supported by ACS RSG-05-116-01-CSM and NIH
grants CA130104 and CA109956. Moores UCSD Cancer Center is an
NCI-sponsored Comprehensive Cancer Center supported by NCI
Specialized Support Grant P30 CA23100.
Conflict of interest None to disclose
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. NCI-Pancreatic Cancer Progress Review Group. National Cancer
Institute Strategic plan for addressing the recommendations of the
Pancreatic Cancer Progress Review Group. PANC-PRG Imple-
mentation Plan. Bethesda: National Cancer Institute; 2002.
2. National Cancer Institute PDQ Database. Available online at
http://www.cancer.gov/cancertopics/pdq
3. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics.
Nat Rev. 2002;2:897–909.
4. Aguire AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner
J, et al. Activated Kras and Ink4a/Arf deficiency cooperate to
produce metastatic pancreatic ductal adenocarcinoma. Genes Dev.
2003;17:3112–26.
5. Hingorani SR, Petricoin III EF, Maitra A, Rajapakse V, King C,
Jacobetz MA, et al. Preinvasive and invasive ductal pancreatic
cancer and its early detection in the mouse. Cancer Cell.
2003;4:437–50.
6. Burden-Gulley SM, Pendergast M, Lemmon V. The role of cell
adhesion molecule L1 in axonal extension, growth cone motility,
and signal transduction. Cell Tissue Res. 1997;290:415–22.
7. Silletti S, Altevogt P, Montgomery AMP. L1 cell adhesion
molecule (CD171). CD171 guide for the International Workshop
in Human Leukocyte Differentiation Antigens and the online
“Protein Reviews on the Web” (PROW) (www.ncbi.nlm.nih.gov/
prow). Prow. 2000;1:31–7.
8. Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A,
Smirnov A, et al. L1 expression as a predictor of progression and
survival in patients with uterine and ovarian carcinomas. Lancet.
2003;362:869–75.
9. Fogel M, Mechtersheimer S, Huszar M, Smirnov A, Abu-Dahi A,
Tilgen W, et al. L1 adhesion molecule (CD 171) in development
and progression of human malignant melanoma. Cancer Letts.
2003;189:237–47.
10. Daponte A, Kostopoulou E, Kollia P, Papamichali R, Vanakara P,
Hadjichristodoulou C, et al. L1-CAM in ovarian serous neo-
plasms. Eur J Gvnaecol Oncol. 2008;29:26–30.
11. Kaifi JT, Heidtmann S, Schurr PG, Reichelt U, Mann O, Yekebas
EF, et al. Absence of L1 in pancreatic masses distinguishes
adenocarcinomas from poorly differentiated neuroendocrine
tumors. Anticancer Res. 2006;26:1167–70.
356 Tumor Biol. (2011) 32:347–35712. Muerkoster SS, Werbing V, Sipos B, Debus MA, Witt M,
Grossmann M, et al. Drug-induced expression of the cellular
adhesion molecule L1CAM confers anti-apoptotic protection and
chemoresistance in pancreatic ductal adenocarcinoma cells.
Oncogene. 2007;26:2759–68.
13. Silletti S, Yebra M, Perez B, Cirulli V, McMahon M, Montgomery
AMP. The cell adhesion molecule L1 promotes a motile and
invasive phenotype via sustained MAP-kinase activation, gene
transcription and induction of integrin-dependent migration. J Biol
Chem. 2004;279:28880–8.
14. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P,
Brabletz T, et al. L1, a novel target of β-catenin signaling,
transforms cells and is expressed at the invasive front of colon
cancers. J Cell Biol. 2005;168:633–42.
15. Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T,
et al. Expression of L1-CAM and ADAM10 in human colon cancer
cells induces metastasis. Cancer Res. 2007;67:7703–12.
16. Cheng L, Lemmon S, Lemmon V. RanBPM is an L1-interacting
protein that regulates L1-mediated mitogen-activated protein
kinase activation. J Neurochem. 2005;94:1102–10.
17. Gast D, Riedle S, Issa Y, Pfiefer M, Beckhove P, Sanderson MP, et
al. The cytoplasmic part of L1-CAM controls growth and gene
expression in human tumors that is reversed by therapeutic
antibodies. Oncogene. 2008;27:1281–9.
18. Schaefer AW, Kamiguchi H, Wong EV, Beach CM, Landreth G,
Lemmon V. Activation of the MAPK signal cascade by the neural
cell adhesion molecule L1 requires L1 internalization. J Biol
Chem. 1999;274:37965–73.
19. Chen MM, Lee C-Y, Leland HA, Lin GY, Montgomery AM,
Silletti S. Inside-out regulation of L1 conformation, integrin
binding, proteolysis, and concomitant cell migration. Mol Biol
Cell. 2010;21:1671–85.
20. Bouvet M, Gamagami RA, Gilpin EA, Romeo O, Sasson A,
Easter D, et al. Factors influencing survival after resection for
periampullary neoplasms. Am J Surg. 2000;180:13–7.
21. Kajiji SM (1984) Intraneoplastic diversity in human pancreatic
cancer. Dissertation, Brown University
22. Beer S, Oleszewski M, Gutwein P, Geiger C, Altevogt P.
Metalloproteinase-mediated release of the ectodomain of L1
adhesion molecule. J Cell Sci. 1999;112:2667–75.
23. Nayeem N, Silletti S, Yang X, Lemmon VP, Reisfeld RA, Stallcup
WB, et al. A potential role for the plasmin(ogen) system in the
posttranslational cleavage of the neural cell adhesion molecule L1.
J Cell Sci. 1999;112:4739–49.
24. Wong EV, Schaefer AW, Landreth G, Lemmon V. Involvement of
p90rsk in neurite outgrowth mediated by the cell adhesion
molecule L1. J Biol Chem. 1996;271:18217–23.
25. Herron LR, Hill M, Davey F, Gunn-Moore FJ. The intracellular
interactions of the L1 family of cell adhesion molecules. Biochem
J. 2009;419:519–31.
26. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P,
et al. Global, in vivo, and site-specific phosphorylation dynamics
in signaling networks. Cell. 2006;127:635–48.
27. Shimizu T, Matsuoka Y, Shirasawa T. Biological significance of
isoaspartate and its repair system. Biol Pharm Bull. 2005;28:1590–6.
28. Dahlin-Huppe K, Berglund EO, Ranscht B, Stallcup WB.
Mutational analysis of the L1 neuronal cell adhesion molecule
identifies membrane-proximal amino acids of the cytoplasmic
domain that are required for cytoskeletal anchorage. Mol Cell
Neurosci. 1997;9:144–56.
29. Chen MM, Leland HA, Lee C-Y, Silletti S. Tyrosine and serine
phosphorylation regulate the conformation and subsequent threo-
nine phosphorylation of the L1 cytoplasmic domain. Biochem
Biophys Res Commun. 2009;389:257–64.
30. Junghans RP, Stone AL, Lewis MS. Biophysical characterization
of a recombinant soluble interleukin 2 receptor (Tac). Evidence
for a monomeric structure. J Biol Chem. 1996;271:10453–60.
31. Meredith Jr JE, Kiosses WB, Takada Y, Schwartz MA. Mutational
analysis of cell cycle inhibition by integrin β1c. J Biol Chem.
1999;274:8111–6.
32. Primiano T, Baig M, Maliyekkel A, Chang B-D, Fellars S, Sadhu
J, et al. Identification of potential anticancer drug targets through
the selection of growth-inhibitory genetic suppressor elements.
Cancer Cell. 2003;4:41–53.
33. Surette MG, Stock JB. Role of α-helical coiled-coil interactions in
receptor dimerization, signaling, and adaptation during bacterial
chemotaxis. J Biol Chem. 1996;271:17966–73.
34. Severs JC, Froland WA. Dimerization of a PACAP peptide
analogue in DMSO via asparagines and aspartic acid residues. J
Pharm Sci. 2007;97:1246–56.
35. Curnis F, Longhi R, Crippa L, Cattaneo A, Dondossola E, Bachi
A, et al. Spontaneous formation of L-isoaspartate and gain of
function in fibronectin. J Biol Chem. 2006;281:36466–76.
36. Gupta R, Srivastava OP. Effect of deamidation of asparagine 146
on functional and structural properties of human lens αB-
crystallin. J Biol Chem. 2004;279:44258–69.
37. Ramachandran GN. Stereochemistry of collagen. Int J Pept
Protein Res. 1988;31:1–16.
Tumor Biol. (2011) 32:347–357 357